title: Oral adenoviral-based vaccines: historical perspective and future opportunity.
abstract: Adenoviral vaccines delivered orally have been used for decades to prevent respiratory illness, but are now being seriously explored again as a platform technology to make vaccines against a variety of pathogens. Years of use in military populations as a preventative measure for adenoviral infection have demonstrated the safety of oral administration of adenovirus. The advantages of using this approach as a platform technology for vaccines include rapid development and distribution, as well as ease of administration. Recent discoveries may allow this platform approach to reach the clinic within a few years.
authors.affiliation: Vaxart, Inc., 600 Townsend St, Suite 120E, San Francisco, CA 94103, USA. stucker@vaxart.com
authors.forename: Sean N
authors.initials: SN
authors.lastname: Tucker
authors.forename: Debora W
authors.initials: DW
authors.lastname: Tingley
authors.forename: Ciaran D
authors.initials: CD
authors.lastname: Scallan
mesh_terms: D000256:Adenoviridae / Q000235:genetics / Q000276:immunology*; D000257:Adenoviridae Infections / Q000517:prevention & control*; D000284:Administration, Oral; D000818:Animals; D005822:Genetic Vectors; D006801:Humans; D012140:Respiratory Tract Diseases / Q000517:prevention & control; D014765:Viral Vaccines / Q000008:administration & dosage*
chemical_list: D014765:Viral Vaccines